Phototherapeutic laser keratectomy for corneal surface irregularities

Interventional procedures guidance
Published: 22 September 2010
nice.org.uk/guidance/ipg358

Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

1 Guidance

1.1 Current evidence on the safety and efficacy of phototherapeutic laser keratectomy for corneal surface irregularities is adequate to support the use of this procedure provided that normal arrangements are in place for clinical governance, consent and audit.
1.2 Patient selection and treatment should be carried out only by ophthalmologists who specialise in corneal surgery.

2 The procedure

2.1 Indications and current treatments

2.1.1 Symptomatic corneal surface irregularities may result from a range of pathologies including band keratopathy, corneal scarring, nodular degeneration, epithelial basement membrane dystrophy or other dystrophies. Symptoms may include loss of visual acuity, pain, sensitivity to light and foreign body sensation.

2.1.2 Treatment aims to restore a normal regular corneal surface and adherence between the epithelium and Bowman's membrane (a basement membrane that lies between the outer layer of stratified epithelium and the substance of the cornea) with associated improvement in visual acuity and comfort.

2.1.3 Standard treatment includes lubrication of the ocular surface, bandage contact lens placement or topical medication. Surgical procedures may include anterior stromal puncture, mechanical debridement, lamellar keratoplasty or resurfacing keratectomy using a diamond Burr. Corneal transplantation may be considered in eyes refractory to treatment.

2.2 Outline of the procedure

2.2.1 The aim of phototherapeutic laser keratectomy for corneal surface irregularities is to create a smooth stromal surface to improve postoperative corneal clarity, decrease existing scarring and facilitate subsequent epithelial adhesion.

2.2.2 Local anaesthetic eye drops are applied and the corneal epithelium is mechanically removed. A laser is used to sequentially ablate uniformly thin layers of corneal tissue, creating a smooth surface which then becomes re-epithelialised. Postoperative management consists of an eye pad, topical antibiotics, sedatives and non-steroidal anti-inflammatory drugs.

Sections 2.3 and 2.4 describe efficacy and safety outcomes from the published literature that the Committee considered as part of the evidence about this procedure. For more detailed information on the evidence, see the overview.
2.3 Efficacy

2.3.1 A non-randomised controlled study of 39 patients (42 eyes) reported no significant difference in overall change in best corrected visual acuity (BCVA) between patients treated by phototherapeutic laser keratectomy and those treated by diamond burr polishing at 7-month follow-up (p = 0.6): BCVA improved in 36% (5/14) and 14% (3/21) of eyes, remained unchanged in 64% (9/14) and 81% (17/21) of eyes and worsened in 0% (0/14) and 5% (1/21) of eyes respectively.

2.3.2 In a case series of 211 patients (232 eyes) mean BCVA improved by 1.4 lines from baseline at 2-year follow-up (p < 0.002). No significant difference was reported in BCVA improvement between subgroups of patients with corneal dystrophy, nodular degeneration, corneal scar, or band keratopathy (absolute figures not stated) (p = 0.15).

2.3.3 In a case series of 216 patients (252 eyes), among eyes with recurrent erosion at baseline, further recurrent erosion was reported in 9% (9/103) of eyes at 12-month follow-up.

2.3.4 The case series of 216 patients reported that 100% (29/29) of eyes with band-like keratopathy were pain free by 6-day follow-up.

2.3.5 A case series of 191 patients (203 eyes) reported that significantly fewer patients with bullous keratopathy had severe symptoms of pain, photosensitivity and/or watering at 6-month follow-up (n = 15) compared with baseline (n = 56) (p < 0.017). Similarly, significantly fewer patients with corneal scarring had severe symptoms at 6-month follow-up (n = 4) compared with baseline (n = 13) (p < 0.0001).

2.3.6 The Specialist Advisers listed key efficacy outcomes as visual acuity, ocular surface health, ocular comfort and pain relief.

2.4 Safety

2.4.1 Recurrent keratitis requiring penetrating keratoplasty was reported in 1% (3/232) of eyes at up to 2-year follow-up in the case series of 211 patients.
2.4.2 One occurrence each of progressing keratolysis at 8-day follow-up, circular subepithelial corneal scarring at 5-month follow-up (both requiring penetrating keratoplasty), progressive kerectasia at 6 months (sequelae not reported), and a sterile corneal immune ring at 4-day follow-up, were described in 4 separate case reports.

2.4.3 A loss of BCVA of 2 lines or more was reported in 13% (3/24) of patients at 2-year follow-up in the case series of 211 patients.

2.4.4 Idiopathic iritis and a marginal corneal ulcer developed in 1 eye each at up to 2-year follow-up in the case series of 211 patients.

2.4.5 Mild postoperative haze was reported in 11% (22/203) of eyes in the case series of 191 patients; this resolved in 12 eyes by 6-month follow-up. There was no significant difference in the occurrence of mild haze between patients treated by laser phototherapeutic keratectomy (33% [5/15] of eyes) or by diamond burr polishing (26% [7/27] of eyes) in the non-randomised controlled study of 39 patients at 7-month follow-up (p = 0.38).

2.4.6 The Specialist Advisers identified corneal infection as an adverse event reported in the literature. They considered theoretical adverse events to include epithelial defect, corneal ectasia, scarring and induction of astigmatism or refractive error.

2.5 Other comments

2.5.1 The Committee noted that the published evidence comprised a mixture of different indications and outcomes, but nevertheless they considered that the case for safety and efficacy was adequately supported by this evidence and by specialist advice.

2.5.2 NICE received 3 completed questionnaires from patients treated by the procedure. They reported improvements in quality of life including reduced photosensitivity (which had required sunglasses) and the ability to walk with more confidence.
3 Further information

Information for patients

NICE has produced information on this procedure for patients and carers (‘Understanding NICE guidance’). It explains the nature of the procedure and the guidance issued by NICE, and has been written with patient consent in mind. A large print version is also available.

4 About this guidance

NICE interventional procedure guidance makes recommendations on the safety and efficacy of the procedure. It does not cover whether or not the NHS should fund a procedure. Funding decisions are taken by local NHS bodies after considering the clinical effectiveness of the procedure and whether it represents value for money for the NHS. It is for healthcare professionals and people using the NHS in England, Wales, Scotland and Northern Ireland, and is endorsed by Healthcare Improvement Scotland for implementation by NHSScotland.

This guidance was developed using the NICE interventional procedure guidance process.

We have produced a summary of this guidance for patients and carers. Information about the evidence it is based on is also available.

Changes since publication

3 January 2012: minor maintenance.

Your responsibility

This guidance represents the views of NICE and was arrived at after careful consideration of the available evidence. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have
regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way which would be inconsistent with compliance with those duties.

Copyright

© National Institute for Health and Clinical Excellence 2010. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.

Contact NICE

National Institute for Health and Clinical Excellence
Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT

www.nice.org.uk
nice@nice.org.uk
0845 033 7780

Endorsing organisation

This guidance has been endorsed by Healthcare Improvement Scotland.

Accreditation

© NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).